Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals. (Q38718092)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28631067%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

review article

1 reference

title

Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28631067%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28631067%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Mirjana Bećarević

1 reference

5 September 2017

publication date

1 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28631067%20AND%20SRC:MED&resulttype=core&format=json

Current Rheumatology Reports

23 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28631067%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28631067%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28631067%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

page(s)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28631067%20AND%20SRC:MED&resulttype=core&format=json

14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends

23 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Delineating the deranged immune system in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Catastrophic antiphospholipid syndrome: The current management approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Management of refractory cases of catastrophic antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Obstetric antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Obstetric and vascular APS: same autoantibodies but different diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Strategies of therapeutic complement inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

New milestones ahead in complement-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement deficiencies and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement activation on platelets: implications for vascular inflammation and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement C3 activation is required for antiphospholipid antibody-induced fetal loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti-phospholipid syndrome (APLS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: comment on the article by Sammaritano et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

β₂-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Human umbilical vein endothelial cells synthesize functional C3, C5, C6, C8 and C9 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Autoantibodies against complement components and functional consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement activation by (auto-) antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

21 January 2018

Anti-C1q autoantibodies

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Recurrent venous thromboembolism while on anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Eculizumab for the Treatment of De Novo Thrombotic Microangiopathy Post Simultaneous Pancreas-Kidney Transplantation—A Case Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Targeting the complement system in systemic lupus erythematosus and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Eculizumab in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Eculizumab and renal transplantation in a patient with CAPS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Genetic variants in C5 and poor response to eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Inhibiting the C5-C5a receptor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement component 5a (C5a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-017-0669-1

Complement activation in patients with primary antiphospholipid syndrome

21 January 2018

1 reference

12 December 2020

Antiphospholipid syndrome

1 reference

12 December 2020

High-sensitivity C-reactive protein: discriminator between patients with primary and secondary antiphospholipid syndrome

1 reference

12 December 2020

Platelet C4d is highly specific for systemic lupus erythematosus

1 reference

12 December 2020

Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome

1 reference

12 December 2020

Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients

1 reference

12 December 2020

Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant

1 reference

12 December 2020

Activation of complement mediates antiphospholipid antibody-induced pregnancy loss

1 reference

12 December 2020

Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis

1 reference

12 December 2020

Eculizumab as rescue therapy in severe resistant lupus nephritis.

1 reference

12 December 2020

The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells

1 reference

12 December 2020

Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia

1 reference

12 December 2020

A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice

1 reference

12 December 2020

A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report

1 reference

12 December 2020

Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis

1 reference

12 December 2020